• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of brjpharmLink to Publisher's site
Br J Pharmacol. May 1995; 115(1): 191–197.
PMCID: PMC1908752

ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro.


1. We have characterized the constrictor endothelin receptors present in human isolated blood vessels using ETA and ETB selective agonists and antagonists. 2. Monophasic dose-response curves were obtained for ET-1 with EC50 values of 6.8 nM in coronary artery, 3.9 nM in internal mammary artery, 17.4 nM in pulmonary artery, 14.5 nM in aorta and 3.2 nM in saphenous vein. In coronary artery, ET-2 was equipotent with ET-1 with an EC50 value of 5.7 nM. The non-selective peptide, sarafotoxin 6b, was 2-3 times less potent than ET-1 but the maximum responses to these two were comparable. 3. In each vessel ET-3 was much less active than ET-1. No response was obtained to ET-3 in aorta and pulmonary artery or in up to 50% of coronary artery, mammary artery and saphenous vein preparations. In those preparations that did respond, dose-response curves were incomplete at 300 nM. Variable contractions were also obtained with the ETB-selective agonist, sarafotoxin 6c (S6c). Where responses were detected, although S6c was more potent than ET-1 (EC50 values of 0.6-1.2 nM), the maximum response produced was always less than 20% of that to ET-1. 4. The synthetic ETB agonists, BQ3020 and [1,3,11,15Ala]-ET-1, were without effect in any of the five blood vessels at concentrations up to 3 microM. 5. ET-1-induced vasoconstriction was blocked by the ETA-selective antagonists, BQ123 and FR139317.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990 Dec 20;348(6303):730–732. [PubMed]
  • ARUNLAKSHANA O, SCHILD HO. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. [PMC free article] [PubMed]
  • Bax WA, Aghai Z, van Tricht CL, Wassenaar C, Saxena PR. Different endothelin receptors involved in endothelin-1- and sarafotoxin S6B-induced contractions of the human isolated coronary artery. Br J Pharmacol. 1994 Dec;113(4):1471–1479. [PMC free article] [PubMed]
  • Bax WA, Bos E, Saxena PR. Heterogeneity of endothelin/sarafotoxin receptors mediating contraction of the human isolated saphenous vein. Eur J Pharmacol. 1993 Aug 3;239(1-3):267–268. [PubMed]
  • Benigni A, Zoja C, Corna D, Orisio S, Longaretti L, Bertani T, Remuzzi G. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int. 1993 Aug;44(2):440–444. [PubMed]
  • Cacoub P, Dorent R, Maistre G, Nataf P, Carayon A, Piette C, Godeau P, Cabrol C, Gandjbakhch I. Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. Am J Cardiol. 1993 Feb 15;71(5):448–450. [PubMed]
  • Chester AH, O'Neil GS, Allen SP, Luu TN, Tadjkarimi S, Yacoub MH. Effect of endothelin on normal and diseased human coronary arteries. Eur J Clin Invest. 1992 Mar;22(3):210–213. [PubMed]
  • Clozel M, Watanabe H. BQ-123, a peptidic endothelin ETA receptor antagonist, prevents the early cerebral vasospasm following subarachnoid hemorrhage after intracisternal but not intravenous injection. Life Sci. 1993;52(9):825–834. [PubMed]
  • Costello KB, Stewart DJ, Baffour R. Endothelin is a potent constrictor of human vessels used in coronary revascularization surgery. Eur J Pharmacol. 1990 Sep 21;186(2-3):311–314. [PubMed]
  • Cristol JP, Warner TD, Thiemermann C, Vane JR. Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat. Br J Pharmacol. 1993 Mar;108(3):776–779. [PMC free article] [PubMed]
  • Davenport AP, Maguire JJ. Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans? Trends Pharmacol Sci. 1994 Jan;15(1):9–11. [PubMed]
  • Davenport AP, Nunez DJ, Hall JA, Kaumann AJ, Brown MJ. Autoradiographical localization of binding sites for porcine [125I]endothelin-1 in humans, pigs, and rats: functional relevance in humans. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S166–S170. [PubMed]
  • Davenport AP, O'Reilly G, Kuc RE. Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type. Br J Pharmacol. 1995 Mar;114(6):1110–1116. [PMC free article] [PubMed]
  • Grossman E, Rosenthal T, Peleg E, Holmes C, Goldstein DS. Oral yohimbine increases blood pressure and sympathetic nervous outflow in hypertensive patients. J Cardiovasc Pharmacol. 1993 Jul;22(1):22–26. [PubMed]
  • Deray G, Carayon A, Le Hoang P. Increased endothelin level after cyclosporine therapy. Ann Intern Med. 1991 May 1;114(9):809–809. [PubMed]
  • Fogo A, Hellings SE, Inagami T, Kon V. Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity. Kidney Int. 1992 Sep;42(3):770–774. [PubMed]
  • Franco-Cereceda A. Endothelin- and neuropeptide Y-induced vasoconstriction of human epicardial coronary arteries in vitro. Br J Pharmacol. 1989 Jul;97(3):968–972. [PMC free article] [PubMed]
  • Fukuroda T, Kobayashi M, Ozaki S, Yano M, Miyauchi T, Onizuka M, Sugishita Y, Goto K, Nishikibe M. Endothelin receptor subtypes in human versus rabbit pulmonary arteries. J Appl Physiol (1985) 1994 May;76(5):1976–1982. [PubMed]
  • Godfraind T. Evidence for heterogeneity of endothelin receptor distribution in human coronary artery. Br J Pharmacol. 1993 Nov;110(3):1201–1205. [PMC free article] [PubMed]
  • Grover GJ, Dzwonczyk S, Parham CS. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res. 1993 Sep;27(9):1613–1618. [PubMed]
  • Harrison VJ, Randriantsoa A, Schoeffter P. Heterogeneity of endothelin-sarafotoxin receptors mediating contraction of pig coronary artery. Br J Pharmacol. 1992 Mar;105(3):511–513. [PMC free article] [PubMed]
  • Hay DW, Luttmann MA, Hubbard WC, Undem BJ. Endothelin receptor subtypes in human and guinea-pig pulmonary tissues. Br J Pharmacol. 1993 Nov;110(3):1175–1183. [PMC free article] [PubMed]
  • Haynes WG, Webb DJ. Endothelium-dependent modulation of responses to endothelin-I in human veins. Clin Sci (Lond) 1993 Apr;84(4):427–433. [PubMed]
  • Hemsén A, Franco-Cereceda A, Matran R, Rudehill A, Lundberg JM. Occurrence, specific binding sites and functional effects of endothelin in human cardiopulmonary tissue. Eur J Pharmacol. 1990 Dec 4;191(3):319–328. [PubMed]
  • Hughes AD, Thom SA, Woodall N, Schachter M, Hair WM, Martin GN, Sever PS. Human vascular responses to endothelin-1: observations in vivo and in vitro. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S225–S228. [PubMed]
  • Ihara M, Ishikawa K, Fukuroda T, Saeki T, Funabashi K, Fukami T, Suda H, Yano M. In vitro biological profile of a highly potent novel endothelin (ET) antagonist BQ-123 selective for the ETA receptor. J Cardiovasc Pharmacol. 1992;20 (Suppl 12):S11–S14. [PubMed]
  • Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A. 1989 Apr;86(8):2863–2867. [PMC free article] [PubMed]
  • Itoh S, Sasaki T, Ide K, Ishikawa K, Nishikibe M, Yano M. A novel endothelin ETA receptor antagonist, BQ-485, and its preventive effect on experimental cerebral vasospasm in dogs. Biochem Biophys Res Commun. 1993 Sep 15;195(2):969–975. [PubMed]
  • Karet FE, Kuc RE, Davenport AP. Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney. Kidney Int. 1993 Jul;44(1):36–42. [PubMed]
  • Kiowski W, Linder L. Reversal of endothelin-1-induced vasoconstriction by nifedipine in human resistance vessels in vivo in healthy subjects. Am J Cardiol. 1992 Apr 15;69(12):1063–1066. [PubMed]
  • Liu JJ, Casley D, Wojta J, Gallicchio M, Dauer R, Johnston CI, Buxton BF. Effects of calcium- and ETA-receptor antagonists on endothelin-induced vasoconstriction and levels of endothelin in the human internal mammary artery. Clin Exp Pharmacol Physiol. 1994 Jan;21(1):49–57. [PubMed]
  • Lüscher TF, Yang Z, Tschudi M, von Segesser L, Stulz P, Boulanger C, Siebenmann R, Turina M, Bühler FR. Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins. Circ Res. 1990 Apr;66(4):1088–1094. [PubMed]
  • McKay KO, Black JL, Diment LM, Armour CL. Functional and autoradiographic studies of endothelin-1 and endothelin-2 in human bronchi, pulmonary arteries, and airway parasympathetic ganglia. J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S206–S209. [PubMed]
  • McNamara DB, Light JT, Minkes RK, Saroyan RM, Kvamme P, Rowe N, Webb WR, Fox L, Kerstein MD, Mills NL, et al. Comparative effects of endothelin (ET-1) and U46619 on human saphenous vein and gastroepiploic artery, sources of human autologous grafts. Mol Cell Biochem. 1992 Nov 4;117(1):81–85. [PubMed]
  • Maguire JJ, Bacon CR, Fujimoto M, Davenport AP. Myricerone caffeoyl ester (50-235) is a non-peptide antagonist selective for human ETA receptors. J Hypertens. 1994 Jun;12(6):675–680. [PubMed]
  • Maguire JJ, Kuc RE, O'Reilly G, Davenport AP. Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vitro. Br J Pharmacol. 1994 Sep;113(1):49–54. [PMC free article] [PubMed]
  • Molenaar P, Kuc RE, Davenport AP. Characterization of two new ETB selective radioligands, [125I]-BQ3020 and [125I]-[Ala1,3,11,15]ET-1 in human heart. Br J Pharmacol. 1992 Nov;107(3):637–639. [PMC free article] [PubMed]
  • Okamura T, Matsumoto T, Ikemoto F, Toda N. Mechanisms of the biphasic responses to endothelin-3 in dog coronary arteries. Br J Pharmacol. 1992 Dec;107(4):1037–1041. [PMC free article] [PubMed]
  • Saetrum Opgaard O, Adner M, Gulbenkian S, Edvinsson L. Localization of endothelin immunoreactivity and demonstration of constrictory endothelin-A receptors in human coronary arteries and veins. J Cardiovasc Pharmacol. 1994 Apr;23(4):576–583. [PubMed]
  • Papadopoulos SM, Gilbert LL, Webb RC, D'Amato CJ. Characterization of contractile responses to endothelin in human cerebral arteries: implications for cerebral vasospasm. Neurosurgery. 1990 May;26(5):810–815. [PubMed]
  • Riezebos J, Watts IS, Vallance PJ. Endothelin receptors mediating functional responses in human small arteries and veins. Br J Pharmacol. 1994 Feb;111(2):609–615. [PMC free article] [PubMed]
  • Sakurai T, Yanagisawa M, Masaki T. Molecular characterization of endothelin receptors. Trends Pharmacol Sci. 1992 Mar;13(3):103–108. [PubMed]
  • Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990 Dec 20;348(6303):732–735. [PubMed]
  • Seo B, Oemar BS, Siebenmann R, von Segesser L, Lüscher TF. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 1994 Mar;89(3):1203–1208. [PubMed]
  • Sokolovsky M. Endothelins and sarafotoxins: receptor heterogeneity. Int J Biochem. 1994 Mar;26(3):335–340. [PubMed]
  • Sørensen SS, Madsen JK, Pedersen EB. Systemic and renal effect of intravenous infusion of endothelin-1 in healthy human volunteers. Am J Physiol. 1994 Mar;266(3 Pt 2):F411–F418. [PubMed]
  • Tomita K, Ujiie K, Nakanishi T, Tomura S, Matsuda O, Ando K, Shichiri M, Hirata Y, Marumo F. Plasma endothelin levels in patients with acute renal failure. N Engl J Med. 1989 Oct 19;321(16):1127–1127. [PubMed]
  • Urade Y, Fujitani Y, Oda K, Watakabe T, Umemura I, Takai M, Okada T, Sakata K, Karaki H. An endothelin B receptor-selective antagonist: IRL 1038, [Cys11-Cys15]-endothelin-1(11-21) FEBS Lett. 1992 Oct 12;311(1):12–16. [PubMed]
  • Urade Y, Fujitani Y, Oda K, Watakabe T, Umemura I, Takai M, Okada T, Sakata K, Karaki H. An endothelin B receptor-selective antagonist: IRL 1038, [Cys11- Cys15]-endothelin-1(11-21) FEBS Lett. 1994 Mar 28;342(1):103–103. [PubMed]
  • Wei CM, Lerman A, Rodeheffer RJ, McGregor CG, Brandt RR, Wright S, Heublein DM, Kao PC, Edwards WD, Burnett JC., Jr Endothelin in human congestive heart failure. Circulation. 1994 Apr;89(4):1580–1586. [PubMed]
  • White DG, Garratt H, Mundin JW, Sumner MJ, Vallance PJ, Watts IS. Human saphenous vein contains both endothelin ETA and ETB contractile receptors. Eur J Pharmacol. 1994 May 23;257(3):307–310. [PubMed]
  • Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988 Mar 31;332(6163):411–415. [PubMed]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • GSS
    Published GSS sequences
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...